It is a common practice for pharma and biotech companies to file for label expansions of existing drugs. The successful label expansion of approved drugs could boost their commercial potential.
Earlier in the week, Sanofi (SNY) announced that Priftin was approved in the U.S. for another indication. The drug was approved in combination with isoniazid (INH) for the treatment of latent tuberculosis infection in patients (aged two years and older) at high risk of progression to tuberculosis (TB) disease. The drug was approved on a priority basis.
We note that Priftin has been approved in the U.S. for almost 16 years for the treatment of active pulmonary TB caused by mycobacterium tuberculosis. The drug must be used in combination with one or more antituberculosis drugs.
However, the drug is yet to be available outside the U.S. Sanofi has said that it is looking to get Priftin approved in other countries as well.
As per the World Health Organization, around 9 million people worldwide were affected by this deadly disease and 1.5 million (16.7%) died from it.
Sanofi is developing a vaccine in a phase II study for the treatment of TB.
Johnson & Johnson’s (JNJ) Sirturo is another approved product for TB.
Sanofi carries a Zacks Rank #4 (Sell). Some better-ranked companies in the health care space are Allergan (AGN) and AbbVie Inc. (ABBV). While Allergan holds a Zacks Rank #1 (Strong Buy), AbbVie carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment